13 / 210
Ponencias
13
en la degradación de la fibrina, por lo que una alteración en la
regulación de este sistema también puede contribuir a la trombogé-
nesis, mientras que una activación excesiva favorecería la aparición
de hemorragias. Contemplar la trombosis desde la óptica de la
fibrinólisis y la proteólisis va a permitir el desarrollo de nuevas
estrategias encaminadas a reducir la principal causa de mortalidad
en nuestro medio.
Bibliografía
1. Páramo JA, Alfaro MJ, Rocha E. Postoperative changes in the plas-
matic levels of tissue-type plasminogen activator and its fast-acting
inhibitor-relationship to deep vein thrombosis and influence of pro-
phylaxis.Thromb Haemost 1985;54:713-6.
2. Páramo JA, Arcas R, Herreros J, Cuesta B, Llorens R, Rocha E. Fibri-
nolysis after heart transplantation. Thromb Haemost 1988;59:123.
3. Páramo JA, Rifón J, Llorens R, Casares J, Paloma MJ, Rocha E.
Intra- and postoperative fibrinolysis in patients undergoing car-
diopulmonary bypass surgery. Haemostasis 1991;21:58-64.
4. Rocha E, Alfaro MJ, Páramo JA, Cañadell JM. Preoperative identifi-
cation of patients at high risk of deep venous thrombosis despite pro-
phylaxis in total hip replacement. Thromb Haemost 1988;59:93-5.
5. Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Dog-
gen CJ, et al. Venous thrombosis risk associated with plasma hypofi-
brinolysis is explained by elevated plasma levels of TAFI and PAI-1.
Blood 2010;116:113-21.
6. Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-ac-
ting inhibitor of plasminogen activator in response to endotoxin sti-
mulation. J Clin Invest 1985;75:818-24.
7. Páramo JA. Coagulación intravascular diseminada. Med Clin (Barc)
2006;127:785-9.
8. Páramo JA, Fernández Díaz FJ, Rocha E. Plasminogen activator inhi-
bitor activity in bacterial infection. Thromb Haemost 1988;59:451-4.
9. Páramo JA, Pérez JL, Serrano M, Rocha E. Types 1 and 2 plasmi-
nogen activator inhibitor and tumor necrosis factor alpha in patients
with sepsis.Thromb Haemost 1990;64:3-6.
10. Muñoz MC, Montes R, Hermida J, Orbe J, Páramo JA, Rocha E.
Effect of the administration of recombinant hirudin and/or tissue-plas-
minogen activator (t-PA) on endotoxin-induced disseminated intravas-
cular coagulation model in rabbits. Br J Haematol 1999;105:117-21.
11. Hermida J, Montes R, Muñoz MC, Orbe J, Páramo JA, Rocha E.
Effects of low molecular weight heparin, alone or combined with
antithrombin III, on mortality, fibrin deposits and hemostatic para-
meters in endotoxin-induced disseminated intravascular coagulation
in rabbits. Am J Hematol 1999;60:6-11.
12. Lorente L, Martín MM, Borreguero-León JM, Solé-Violán J, Ferre-
res J, Labarta L, et al. Sustained high plasma plasminogen activator
inhibitor-1 levels are associated with severity and mortality in septic
patients. Thromb Res 2014;134:182-6.
13. Jurado M, Páramo JA, Gutiérrez-Pimentel M, Rocha E. Fibrinolytic
potential and antiphospholipid antibodies in systemic lupus erythematosus
and other connective tissue disorders. ThrombHaemost 1992;68:516-20.
14. Rocha E, Páramo JA, Fernández FJ, Cuesta B, Hernández M, Palo-
ma MJ, et al. Clotting activation and impairment of fibrinolysis in
malignancy. Thromb Res 1989;54:699-707.
15. Paramo JA, Colucci M, Collen D, van de Werf F. Plasminogen acti-
vator inhibitor in the blood of patients with coronary artery disease.
Br Med J 1985;291:573-4.
16. Rifón J, Páramo JA, Panizo C, Montes R, Rocha E. The increase
of plasminogen activator inhibitor activity is associated with graft
occlusion in patients undergoing aorto-coronary bypass surgery. Br
J Haematol 1997;99:262-7.
17. Gorog DA. Prognostic value of plasma fibrinolysis activation mar-
kers in cardiovascular disease. J Am Coll Cardiol 2010;55:2701-9.
18. Sahebkar A, Catena C, Ray KK, Vallejo-Vaz AJ, Reiner Ž, Sechi
LA, et al. Impact of statin therapy on plasma levels of plasmino-
gen activator inhibitor-1. A systematic review and meta-analysis of
randomised controlled trials. Thromb Haemost 2016;116:162-71.
19. Orbe J,AlexandruN, Roncal C, BelzunceM, Bibiot P, Rodríguez JA, et al.
Lack of TAFI increases brain damage and microparticle generation after
thrombolytic therapy in ischemic stroke.Thromb Res 2015;136:445-50.
20. Rodríguez JA, Orbe J, Páramo JA. Metalloproteasas, remode-
lado vascular y síndromes aterotrombóticos. Rev Esp Cardiol
2007;60:959-67.
21. Páramo JA, Orbe J, Fernández J. Fibrinolysis/proteolysis balance in
stable angina pectoris in relation to angiographic findings. Thromb
Haemost. 2001;86:636-9.
22. Montero I, Orbe J, Varo N, Beloqui O, Monreal JI, Rodríguez JA,
et al. C-reactive protein induces matrix metalloproteinase-1 and -10
in human endothelial cells: implications for clinical and subclinical
atherosclerosis. J Am Coll Cardiol 2006;47:1369-78.
23. Orbe J, Rodríguez JA, Calvayrac O, Rodríguez-Calvo R, Rodríguez C,
Roncal C, et al. Matrix metalloproteinase-10 is upregulated by throm-
bin in endothelial cells and increased in patients with enhanced throm-
bin generation. Arterioscler Thromb Vasc Biol 2009;29:2109-16.
24. Orbe J, Montero I, Rodríguez JA, Beloqui O, Roncal C, Páramo
JA. Independent association of matrix metalloproteinase-10, car-
diovascular risk factors and subclinical atherosclerosis. J Thromb
Haemost 2007;5:91-7.
25. Coll B, Rodríguez JA, Craver L, Orbe J, Martínez-Alonso M, Ortiz
A, et al. Serum levels of matrix metalloproteinase-10 are associated
with the severity of atherosclerosis in patients with chronic kidney
disease. Kidney Int 2010;78:1275-80.
26. Rodríguez JA, SobrinoT, Orbe J, PurroyA, Martínez-Vila E, Castillo J, et
al. proMetalloproteinase-10 is associated with brain damage and clinical
outcome in acute ischemic stroke. J Thromb Haemost 2013;11:1464-73.
27. Martínez-Aguilar E, Gómez-Rodríguez V, Orbe J, Rodríguez JA,
Fernández-Alonso L, Roncal C, et al. Matrix metalloproteinase 10
is associated with disease severity and mortality in patients with
peripheral arterial disease. J Vasc Surg 2015;61:428-35.
28. Lorente L, Martín MM, Labarta L, Díaz C, Solé-Violán J, Blan-
quer J, et al. Matrix metalloproteinase-9, -10, and tissue inhibitor of
matrix metalloproteinases-1 blood levels as biomarkers of severity
and mortality in sepsis. Crit Care 2009;13:R158.
29. Lorente L, Martín MM, Solé-Violán J, Blanquer J, Labarta L, Díaz
C, et al. Association of sepsis-related mortality with early increase
of TIMP-1/MMP-9 ratio. PLoS One 2014;9:e94318.
30. Lorente L, Martín MM, López P, Ramos L, Blanquer J, Cáceres JJ,
et al. Association between serum tissue inhibitor of matrix metallo-
proteinase-1 levels and mortality in patients with severe brain trauma
injury. PLoS One 2014;9:e94370.
31. Lorente L, Martín MM, Ramos L, Cáceres JJ, Solé-Violán J, Argue-
so M, et al. Tissue inhibitor of matrix metalloproteinase-1 levels are
associated with mortality in patients with malignant middle cerebral
artery infarction. BMC Neurol 2015 11;15:111.
32. Orbe J, Barrenetxe J, Rodríguez JA,Vivien D, Orset C, ParksWC, et al.
Matrix metalloproteinase-10 effectively reduces infarct size in experi-
mental stroke by enhancing fibrinolysis via a thrombin-activatable fibri-
nolysis inhibitor-mediated mechanism. Circulation 2011;124:2909-19.
33. Orbe J, Rodríguez JA, Sánchez-Arias JA, Salicio A, Belzunce M,
Ugarte A, et al. Discovery and safety profiling of a potent preclini-
cal candidate, (4-[4-[[(3R)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]
decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352),
for the prevention and treatment of hemorrhage. J Med Chem
2015;58:2941-57.